+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 3
Age: 2Years - 30Years
All Genders
ID07377032

Study of L-serine Supplementation for Children and Young Adults With GRIN-related Neurodevelopmental Disorders Using Randomized Placebo-Controlled N-of-1 Trials

Led by Meyer Children's Hospital IRCCS · Updated on 2026-01-29

40

Participants Needed

3

Research Sites

N/A

Total Duration

AI-Summary

What This Trial Is About

Researchers are evaluating whether L-serine dietary supplementation can improve overall clinical functioning in children and young adults aged 2 to 30 years who have GRIN-related neurodevelopmental disorders caused by loss-of-function variants in GRIN1, GRIN2A, GRIN2B, or GRIN2D genes. These disorders can lead to epilepsy, intellectual disability, behavior issues, sleep problems, and motor impairments. The study also aims to assess the safety and tolerability of L-serine and explore neurophysiological biomarkers that might indicate treatment response. Participants will receive both L-serine and a placebo maltodextrin powder in alternating 3-month treatment periods within cycles lasting 6 months each. They will take the assigned oral powder three times daily at a dose of 500 mgkgday, up to a maximum of 30 gday for those weighing 60 kg or more. Each treatment period begins with a 7-day washout phase, and participants are expected to complete at least two cycles up to four. The study uses a randomised, double-blind, placebo-controlled n-of-1 trial design where each participant serves as their own control. During the study, participants will complete a 4-week baseline observation period followed by regular clinic visits for clinical exams, safety lab tests, and standardized assessments of global clinical status, behavior, cognition, motor skills, and sleep quality. Those with epilepsy will keep a seizure diary and undergo EEG assessments after each treatment period. Selected sites will perform neurophysiological testing using transcranial magnetic stimulation combined with electromyography or EEG. Some participants may also join an optional substudy involving blood samples to create neuronal models for further exploration of treatment effects. Safety monitoring will continue throughout the study with follow-up lasting up to approximately 104 weeks.

CONDITIONS

Brief Title

TAP-GRIN: Interventional Study on Patients With GRIN-related Neurodevelopmental Disorders

Research Team

S

Simona Balestrini, Md, PhD

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here